Fidson Healthcare Plc, a prominent Nigerian pharmaceutical company, has officially commenced a N21 billion Rights Issue, signalling a significant move to bolster its market leadership and drive aggressive expansion. The company held a formal signing ceremony to initiate the process, pending final approvals from regulatory bodies, including the Securities and Exchange Commission (SEC) and the Nigerian Exchange Limited (NGX).

This strategic capital raise aims to generate substantial funds to increase production capacity and fuel ambitious expansion plans across the African continent. The offering involves 600 million new ordinary shares, each priced at N35.00, presented to existing shareholders on a one-for-four basis relative to their holdings as of November 12, 2025.

The Rights Issue follows a period of exceptional financial performance for Fidson, underscoring its robust operational execution and strong market standing. Recent results for the nine months ending September 30, 2025, reveal a remarkable 132% year-on-year increase in Profit After Tax (PAT), reaching N7.97 billion.

This surge in profitability was driven by a 56% rise in revenue, which climbed to N93.08 billion, indicative of strong market demand and an expanding customer base. The company also demonstrated impressive efficiency gains, with Operating Profit growing by 92% to N16.95 billion, reflecting effective cost management strategies.

The N21 billion capital infusion is earmarked for critical investments, including enhancing manufacturing capabilities, fostering product innovation, and penetrating new geographical markets. This move is designed to solidify Fidson’s position as a leading healthcare provider in Nigeria and a formidable player across Africa.

Biola Adebayo, Managing Director/CEO of Fidson Healthcare Plc, emphasized the significance of this capital raise, stating it will cement the company’s status as a foremost healthcare entity in Nigeria and a dominant force continentally. He highlighted the company’s proven ability to innovate and thrive, assuring stakeholders of accelerated growth and sustainable long-term value creation.

Finance Director Imokha Ayebae detailed the financial structure of the Rights Issue, assuring investors of its viability and strategic importance. The proceeds will be strategically deployed for operational optimisation, including technological upgrades and the expansion of product portfolios, urging eligible shareholders to actively participate.

Michael Nzewi, CEO of CardinalStone Partners Limited, the lead issuing house, noted the substantial growth in Fidson’s stock value since its 2019 offering. The current offer price of N35.00, representing a discount to the current market price, is seen as a testament to the company’s impressive growth trajectory and the attractiveness of its shares.

Shareholders registered by the qualification date are strongly encouraged to complete and submit their participation forms along with full payment to designated receiving agents before the closing date. Fidson remains committed to its pursuit of excellence in pharmaceutical manufacturing, stakeholder value, workforce empowerment, and continuous innovation.

Read Original

Keywords: Fidson Healthcare, Rights Issue, N21 billion, pharmaceutical manufacturing, capital raise, African expansion, shareholder value, Nigerian stock market